Summary
27 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 0.8% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it fell by 0.8% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of ¥124.4M.
Profitability in detailIs it financially healthy?
Debt is a burdenIts debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Services and other revenues 81%
- Medicine income 17%
- Equipment Leasing Revenues 1.8%
By region
- CHINA 100%
Services and other revenues brings in 81% of revenue.
Segments in detail